Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Completed

Conditions studied: Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Neurotoxicity Syndrome, Pain, Regional Neuroblastoma, Stage 4 Neuroblastoma, Stage 4S Neuroblastoma

In brief

This research trial is studying how Ch14.18 acts in the body of younger patients with high-risk neuroblastoma. Studying samples of blood from patients with cancer receiving Ch14.18 may help doctors learn more about how this drug is used by the body to develop better ways to give the drug to potentially improve its effectiveness and lessen its side effects.

Key facts

Study ID

NCT01418495

Run by

National Cancer Institute (NCI)

People needed

12

Starts

2011-05-26

Last updated by the study team

2019-10-01

Who can join

Age: any, up to 15. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of high-risk neuroblastoma
• Enrolled on the COG protocol ANBL0032 or ANBL0931 and eligible to receive ch14.18 according to the criteria on these primary treatment protocols
• Parental informed consent and verbal assent of the subject when appropriate

You may not qualify if…

• Prior testing demonstrating the presence of HACA
• Anaphylactic reaction to ch14.18 on a prior treatment cycle

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.